Etanercept in Hidradenitis Suppurativa

Etanercept in Hidradenitis Suppurativa


Etanercept in Hidradenitis Suppurativa

Acronym: null
Other IDs: 2004-004555-19
NCT Number: NCT00329823
Sponsor Collaborators: University of Athens
Funding: Other


HIDRADENITIS SUPPURATIVA CLINICAL TRIAL STATUS

Recruiting Status: Completed
Recruiting Genders: Both
Recruiting Age Groups: Child|Adult|Senior
Interventions: Drug: Etanercept sc 50mg per week for 12 weeks
Phases: Phase 2


CLINICAL STUDY DETAILS & RESULTS

STUDY TYPES: Interventional
STUDY DESIGNS: Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label
Results First Received: No Study Results Posted
Study Result (if available): No Results Available
Primary Completion Date: null
Outcome Measures: Endpoints :|The disease activity index based on a calculated score.|The sum of the [diameter X severity] for each affected area.|Patient’s global assessment of disease activity scores based on a VAS scale|of 1-10.|The number of newly presented lesions.


CLINICAL STUDIES DATES & MILESTONES

First Received: May 23, 2006
Start Date: September 2005
Completion Date: May 2006
Last Updated: May 23, 2006
last Verified: May 2006


Source: https://ClinicalTrials.gov/show/NCT00329823


Public Domain Source: ClinicalTrials.gov query for “Hidradenitis suppurativa” clinical studies (last updated January 2016).


Tags:

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2017 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Translate »

Log in with your credentials

Forgot your details?